Close Menu

More articles about Research & Discovery

When Applied Biosystems introduced a commercial version of the ICAT reagent technology last March, proteomics researchers had high hopes that at long last a method for performing high-throughput differential protein analysis had emerged to provide an alternative to the drudgery of 2D gel electrophoresis. Subscribers: click headline for more

Pharmaceutical companies have long relied on x-ray crystallography to help refine their candidate small molecule drugs, but a deal signed last week between Structural Genomix (SGX) of San Diego and Heidelberg-based Graffinity may be the first to combine the new breed of high-throughput protein crystallography with array-based approaches to finding drug leads. Subscribers: click headline for more

IBM continued its penetration of the proteomics market last week, as protein database provider GeneFormatics chose the company to provide computing equipment and support. Subscribers: click headline for more

Two Munich startups, Nanotype and Xerion Pharmaceuticals, have joined forces to develop a protein chip for studying neural stem cell behavior and differentiation, Nanotype said Dec. 13. Subscribers: click headline for more

Subscribers: click headline for more

In previous conference presentations, Scott Patterson, Celera Genomics vice president for proteomics, has indicated that the company is pursuing a focused approach to discovering potential drug targets and markers Subscribers: click headline for more

Oxford GlycoSciences has filed patent applications on 4,000 disease-associated proteins, protein isoforms, and their genes, accomplishing a goal the company set for itself in March 2000, the Abingdon, UK-based company said Dec. 7 Subscribers: click headline for more

Providing further evidence that scientists from diverse disciplines are seeking to apply proteomics techniques to their research, a symposium earlier this month sponsored by the NIH s National Center for Toxicogenomics featured prominent players from the field of proteomics, including Denis Hochstrasser, a founder of GeneProt, and Emanuel Petricoin, a co-director of the joint NCI-FDA clinical proteomics program Subscribers: click headline for more

Subscribers: click headline for more

MDS Proteomics plans to go through with an initial public offering next year to acquire additional funding, the company s new CFO said last week Subscribers: click headline for more

Subscribers: click headline for more

Subscribers: click headline for more

Rounding out the selection of protein analysis equipment for its US proteomics factory, GeneProt has chosen Micromass to install Q-TOF mass spectrometers and liquid chromatography systems valued at $20 million in its North Brunswick, NJ, facility, the companies said last week. In addition, Micromass will make an equity investment of up to $10 million in GeneProt Subscribers: click headline for more

In the past year and a half, for-profit scientific publishers have launched two new research journals devoted to proteomics: Proteomics and Proteome. The latter lasted about four months before Springer -- under new Bertelsmann managers -- pulled the plug Subscribers: click headline for more

In support of its claim to have a hand in both proteomics technology development and discovery, Proteome Systems has signed a research partnership with Eukarion, a privately-held drug company, that will give Proteome Systems a stake in the profits from any drugs developed through the collaboration.

With the number of protein structures growing exponentially, an increasing number of companies are focusing their efforts on structure-based drug design. One of the latest additions is Plexxikon of Berkeley, Calif., founded in December of 1999 by a team of scientists with expertise in cell signaling proteins and their potential as drug targets Subscribers: click headline for more

Subscribers: click headline for more

Like many large pharmaceutical and biotechnology companies, Genentech has made a point of delving into proteomics as a new approach to discovering potential drug targets and therapeutic proteins. The South San Francisco-based company has developed platforms for implementing differential proteomics experiments and mapping protein interactions, using primarily off-the-shelf multi-dimensional chromatography and mass spectrometry. Subscribers: click headline for more

While states such as California and Massachusetts spring more immediately to mind when it comes to homes for proteomics and other biotechnology companies, Michigan, the land of great lakes, great location, has embarked on an ambitious program to prove that proteomics can thrive in the heartland too. Subscribers: click headline for more

Pages

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.